Loading
A phase 1/2 trial of Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Imunon, active and no longer recruiting.
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) is a phase 1/2 interventional study registered as NCT03393884 by Imunon, with 130 participants planned, started 2018-09-05 and due to reach its primary completion in 2024-07-25. Interventions recorded: IMNN-001, Carboplatin, Paclitaxel. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/